Mechanism-Based Design of Parasite-Targeted Artemisinin Derivatives: Synthesis and Antimalarial Activity of New Diamine Containing Analogues
- 1 February 2002
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 45 (5) , 1052-1063
- https://doi.org/10.1021/jm0109816
Abstract
The potent antimalarial activity of chloroquine against chloroquine-sensitive strains can be attributed, in part, to its high accumulation in the acidic environment of the heme-rich parasite food vacuole. A key component of this intraparasitic chloroquine accumulation mechanism is a weak base “ion-trapping” effect whereupon the basic drug is concentrated in the acidic food vacuole in its membrane-impermeable diprotonated form. By the incorporation of amino functionality into target artemisinin analogues, we hoped to prepare a new series of analogues that, by virtue of increased accumulation into the ferrous-rich vacuole, would display enhanced antimalarial potency. The initial part of the project focused on the preparation of piperazine-linked analogues (series 1 (7 − 16)). Antimalarial evaluation of these derivatives demonstrated potent activity versus both chloroquine-sensitive and chloroquine-resistant parasites. On the basis of these observations, we then set about preparing a series of C-10 carba-linked amino derivatives. Optimization of the key synthetic step using a newly developed coupling protocol provided a key intermediate, allyldeoxoartemisinin (17) in 90% yield. Further elaboration, in three steps, provided nine target C-10 carba analogues (series 2 (21 − 29)) in good overall yields. Antimalarial assessment demonstrated that these compounds were 4-fold more potent than artemisinin and about twice as active as artemether in vitro versus chloroquine-resistant parasites. On the basis of the products obtained from biomimetic Fe(II) degradation of the C-10 carba analogue (23), we propose that these analogues may have a mode of action subtly different from that of the parent drug artemisinin (series 1 (7 − 16)) and other C-10 ether derivatives such as artemether. Preliminary in vivo testing by the WHO demonstrated that four of these compounds are active orally at doses of less than 10 mg/kg. Since these analogues are available as water-soluble salts and cannot form dihydroartemisinin by P450-catalyzed oxidation, they represent useful leads that might prove to be superior to the currently used derivatives, artemether and artesunate.Keywords
This publication has 17 references indexed in Scilit:
- The effect of artesunate combined with standard antimalarials against chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum in vitroTransactions of the Royal Society of Tropical Medicine and Hygiene, 1999
- Synthesis, Antimalarial Activity, and Molecular Modeling of Tebuquine AnaloguesJournal of Medicinal Chemistry, 1997
- Mechanism-Based Development of New Antimalarials: Synthesis of Derivatives of Artemisinin Attached to Iron ChelatorsJournal of Medicinal Chemistry, 1995
- Malarial haemozoin/β-haematin supports haem polymerization in the absence of proteinNature, 1995
- Amine peroxides as potential antimalarialsJournal of Medicinal Chemistry, 1989
- Monolayer properties of eight diastereomeric two-chain surfactants at the air/water interface: a resultant of intramolecular and intermolecular forcesJournal of the American Chemical Society, 1988
- Arteether, a new antimalarial drug: synthesis and antimalarial propertiesJournal of Medicinal Chemistry, 1988
- Qinghaosu (Artemisinin): an Antimalarial Drug from ChinaScience, 1985
- Photochemical studies of 7-cis-rhodopsin at low temperatures. Nature and properties of the bathointermediateBiochemistry, 1980
- Lysosomes, pH and the Anti-malarial Action of ChloroquineNature, 1972